Anti-galectin-9 antibodies and therapeutic uses thereof
AssigneePureTech LYT, Inc.
InventorsAleksandra FILIPOVIC, Eric ELENKO, Heather PADEN, Christopher KORTH
Life of this patent
Estimating the term…
Abstract
Disclosed herein are methods for treating solid tumors (e.g., pancreatic ductal adenocarcinoma (PDAC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), cholangiocarcinoma (CAA), renal cell carcinoma (RCC), urothelial, head and neck, breast cancer, lung cancer, or other gastrointestinal solid tumors), using an anti-Galectin-9) antibody, e.g., as a monotherapy or as a combined therapy with an immune checkpoint inhibitor.
Claims39
A method for treating a solid tumor, the method comprising administering to a subject in need thereof an effective amount of an antibody that binds human Galectin-9 (anti-Galectin-9 antibody), wherein the anti-Galectin-9 antibody comprises a light chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 1, a light chain complementarity determining region 2 (CDR2) set forth as SEQ ID NO:
- 2, and a light chain complementarity determining region 3 (CDR3) set forth as SEQ ID NO:
- 3 and/or comprises a heavy chain complementarity determining region 1 (CDR1) set forth as SEQ ID NO:
- 4, a heavy chain complementarity determining region 2 (CDR2) set forth as SEQ ID NO:
- 5, and a heavy chain complementarity determining region 3 (CDR3) set forth as SEQ ID NO:
- 6 and wherein the anti-Galectin-9 antibody is administered to the subject at a dose of about 0.2 mg/kg to about 32 mg/kg,
- wherein the subject has one or more of the following features:
- (i) has no resectable cancer;
- (ii) has no infection by SARS-COV-2;
- (iii) has no active brain or leptomeningeal metastasis;
- and
- (iv) has unresectable metastatic cancer, which is adenocarcinoma, optionally squamous cell carcinoma.
A method for treating a solid tumor, the method comprising administering to a subject in need thereof an effective amount of an antibody that binds human Galectin-9 (anti-Galectin-9 antibody), wherein the anti-Galectin-9 antibody comprises:
- (a) a light chain comprising a light chain variable region (VL), which comprises a light chain (LC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:
- 1, a LC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:
- 2, and a LC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:
- 3 and
- (b) a heavy chain comprising a heavy chain variable region (VH), which comprises a heavy chain (HC) complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO:
- 4, a HC complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO:
- 5, and a HC complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO:
- 6;
- wherein the anti-Galectin-9 antibody is administered to the subject at a dose of about 0.2 mg/kg to about 32 mg/kg once every week.
Dependencies are inferred from the claim text.